CN1256090C - Application in antidepressants preparation of asiatic acid and derivation - Google Patents
Application in antidepressants preparation of asiatic acid and derivation Download PDFInfo
- Publication number
- CN1256090C CN1256090C CN 200310108854 CN200310108854A CN1256090C CN 1256090 C CN1256090 C CN 1256090C CN 200310108854 CN200310108854 CN 200310108854 CN 200310108854 A CN200310108854 A CN 200310108854A CN 1256090 C CN1256090 C CN 1256090C
- Authority
- CN
- China
- Prior art keywords
- acid
- asiatic
- asiatic acid
- madecassic
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Steroid Compounds (AREA)
Abstract
The present invention relates to a new purpose for preparing antidepressant medicine by asiatic acid and derivates thereof. Experiments prove that asiatic acid and derivatives thereof, and a medical composition are medicine with the advantages of safety, high efficiency, stability and low cost for preventing and treating depression, and have high activity. Particularly asiatic acid and compounds such as sodium asiatic acid oxalate have higher activity than doxepin.
Description
Technical field
The present invention relates to the new purposes of ursane type pentacyclic triterpenoid, relate in particular to a kind of new purposes of asiatic acid and derivant thereof, more specifically say to relate to asiatic acid and the new purposes of derivant in the preparation antidepressant drug thereof.
Background technology
The affective disorders of one of five big diseases of world today's harm humans health brings white elephant to human society.Depression in the affective disorders be with remarkable and persistent depressed, behavior is numb and pessimistic and worldweary be one group of disease of principal character.In fact it is very common, so that be called as " common cold " in the mental sickness, it still is serious, life-threatening disease simultaneously, is tormenting the people who counts in the world in necessarily.Therefore, press for safe, efficient, cheap antidepressants.
The medicine that is used for the treatment of depression at present mainly contains tricyclic antidepressants, oxidase inhibitor and 5-hydroxy tryptamine cell reabsorption inhibitor, but untoward reaction is in various degree arranged all, as drowsiness, blurred vision, hypertension, convulsions and hyposexuality etc., be extensive use of thereby limited it.Therefore, searching antidepressants novel, that the untoward reaction effect is little are still imperative.
Herba Centellae total glycosides mainly is made up of asiaticoside (asiaticoside) and asiaticoside (madecassoside), extraction separation obtains from samphire Herba Centellae (Centella asiatica), and depression is had therapeutical effect (referring to Chinese patent CN1387868A and CN1377649A).And asiatic acid (asiatic acid) and its derivant Madecassic acid (madecassic acid) are respectively the aglycons of asiaticoside and asiaticoside, also are to be obtained by extraction separation in the samphire Herba Centellae.
As everyone knows, glycosides and aglycon coexist in plant, and aglycon is the part that glycosides removes sugar, and does not have necessary relation between the activity of the activity of glycosides and aglycon.Glycosides has activity, and the possible non-activity of aglycon as many saponin hemolytic activity is arranged, but its corresponding aglycon does not then have this effect; Glycosides has activity, aglycon also has activity, as main effective ingredient glycyrrhizin of Radix Glycyrrhizae (glycyrrhizin) and aglycon thereof---enoxolone (glycyrrhetinic acid) all have activity (for army building referring to gold, the summer perfect self-cultivation. foreign medical science Chinese medicine fascicle .1994; 16 (1): 13-15).
Have research data to show, asiatic acid and derivant thereof have treatment wound, skin ulcer, anticancer, protect the liver, dull-witted and effect (referring to foreign patent WO96/17819, WO98/23575, WO98/23278, WO98/23574, WO98/37899) that identification is disorderly.But do not see as yet that up to now asiatic acid and derivant thereof are used to prepare the report of antidepressant disease medicament.
Summary of the invention
The technical issues that need to address of the present invention are open asiatic acid and the application of derivant in the preparation antidepressant drug thereof, to satisfy people's needs.
Have in the active skull cap components process of antidepressant effect in screening, the inventor finds in the chemical constituent of Herba Centellae except that the bigger glycoside composition of volatile oil and polarity, non-volatile fat-soluble part (chloroform extraction part) also has very strong antidepressant effect, this part is separated, find that active site is the asiatic centella total aglycon, further separate obtaining asiatic acid and Madecassic acid, all show strong antidepressant effect.Simultaneously, the inventor has carried out big quantity research to other derivants of asiatic acid, confirms all to have antidepressant activity, and has announced part experimental data and analysis result in an embodiment.
The chemical structure of general formula of said asiatic acid and derivant thereof is as follows:
Wherein, R
1Be hydrogen or hydroxyl; R
2For hydrogen, contain straight or branched low alkyl group, alkali metal, alkali earth metal, the ammonium of 1～4 carbon atom or contain a kind of in the organic ammonium of 1～6 carbon atom;
The straight or branched low alkyl group of said 1～4 carbon atom comprises a kind of in methyl, ethyl, propyl group, isopropyl, butyl, isobutyl group, the tert-butyl group or the sec-butyl;
The organic ammonium of said 1～6 carbon atom comprises a kind of in first ammonium, second ammonium, diethyl ammonium, three second ammoniums, third ammonium, different third ammonium, fourth ammonium, isobutyl ammonium, uncle's fourth ammonium or the Zhong Ding ammonium;
Preferably comprise asiatic acid, the asiatic acid methyl ester, the asiatic acid ethyl ester, the asiatic acid propyl ester, asiatic acid sodium, asiatic acid potassium, asiatic acid calcium, asiatic acid magnesium, the asiatic acid ammonium, asiatic acid first ammonium, asiatic acid second ammonium, asiatic acid diethyl ammonium, Herba Centellae triethylenetetraminehexaacetic acid ammonium, Madecassic acid, the Madecassic acid methyl ester, the Madecassic acid ethyl ester, the Madecassic acid propyl ester, Madecassic acid sodium, Madecassic acid potassium, Madecassic acid calcium, Madecassic acid magnesium, the Madecassic acid ammonium, Madecassic acid first ammonium, Madecassic acid second ammonium, a kind of in Madecassic acid diethyl ammonium or the Madecassic acid three second ammoniums.The group such as the table 1 of above-claimed cpd.
Table 1, asiatic acid and relevant derivant thereof
| Sequence number | R 1 | R 2 | The chemical compound title |
| 1 | Hydrogen | Hydrogen | Asiatic acid |
| 2 | Hydrogen | Methyl | The asiatic acid methyl ester |
| 3 | Hydrogen | Ethyl | The asiatic acid ethyl ester |
| 4 | Hydrogen | Propyl group | The asiatic acid propyl ester |
| 5 | Hydrogen | Sodium | Asiatic acid sodium |
| 6 | Hydrogen | Potassium | Asiatic acid potassium |
| 7 | Hydrogen | Calcium | Asiatic acid calcium |
| 8 | Hydrogen | Magnesium | Asiatic acid magnesium |
| 9 | Hydrogen | Ammonium | The asiatic acid ammonium |
| 10 | Hydrogen | The first ammonium | Asiatic acid first ammonium |
| 11 | Hydrogen | The second ammonium | Asiatic acid second ammonium |
| 12 | Hydrogen | The diethyl ammonium | Asiatic acid diethyl ammonium |
| 13 | Hydrogen | Three second ammoniums | Herba Centellae triethylenetetraminehexaacetic acid ammonium |
| 14 | Hydroxyl | Hydrogen | Madecassic acid |
| 15 | Hydroxyl | Methyl | The Madecassic acid methyl ester |
| 16 | Hydroxyl | Ethyl | The Madecassic acid ethyl ester |
| 17 | Hydroxyl | Propyl group | The Madecassic acid propyl ester |
| 18 | Hydroxyl | Sodium | Madecassic acid sodium |
| 19 | Hydroxyl | Potassium | Madecassic acid potassium |
| 20 | Hydroxyl | Calcium | Madecassic acid calcium |
| 21 | Hydroxyl | Magnesium | Madecassic acid magnesium |
| 22 | Hydroxyl | Ammonium | The Madecassic acid ammonium |
| 23 | Hydroxyl | The first ammonium | Madecassic acid first ammonium |
| 24 | Hydroxyl | The second ammonium | Madecassic acid second ammonium |
| 25 | Hydroxyl | The diethyl ammonium | Madecassic acid diethyl ammonium |
| 26 | Hydroxyl | Three second ammoniums | Madecassic acid three second ammoniums |
Said asiatic acid of the present invention and derivant Madecassic acid thereof extract from the samphire Herba Centellae, and document [J.E.Bontems, Bull.Sci.Pharmacol.1941 are arranged; (49): 186-91.] the extracting method of report asiatic acid and Madecassic acid, foreign patent (WO00/63148, WO96/17819) discloses the preparation method of asiatic acid derivant, and the physicochemical data of asiatic acid and derivant thereof carried out detailed report, the present invention repeats no more.
The preparation method of above-mentioned allied compound is as follows:
The preparation method of above-mentioned salt derivative is, asiatic acid or Madecassic acid are dissolved in the certain density alcoholic solution, at a certain temperature, react with corresponding alkali solution, reclaim solvent again, and in certain density ethanol, carry out recrystallization, promptly obtain the salt derivative of asiatic acid, Madecassic acid, referring to foreign patent WO00/63148.
The preparation method of above-mentioned esters derivative is referring to document Shim, P.-J.; Park, J.-H.; Chang, M.-S.; Lim, M.-J.; Kim, D.-H.; Jung, Y.-H.; Jew, S.-s.; Park, E.-H.; Kim, H.-D.Bioorg.Med.Chem.Lett.1996,6,2937. and Singh, B.; Rastogil, R.P.Phytochemistry 1968,7, and 1385. and foreign patent WO96/17819.
Studies show that asiaticoside is different with its aglycon asiatic acid molecular structure, report, do not see the report of asiatic acid antidepressant activity although therefore the antidepressant activity of asiaticoside is existing.As everyone knows, drug metabolism can make the medicine inactivation, also can make it be converted into activity form.Have research data to show, asiaticoside is converted to its aglycon in vivo---and asiatic acid [referring to Rush WR, Murray GR, Graham DJ.Eur J Drug Metab Pharmacokinet.1993Oct-Dec; 18 (4): 323-6; And Grimaldi R, De Ponti F, D ' Angelo L eg.J Ethnopharmacol.1990Feb; 28 (2): 235-41].
The inventor has carried out a large amount of research to asiatic acid and derivant thereof, and the derivant of the asiatic acid that discovery is addressed all has antidepressant activity, and then confirms that asiatic acid is the activity form of asiaticoside at the gastrointestinal tract intracellular metabolite.Directly use asiatic acid, need not be through the metabolism of gastrointestinal tract antibacterial, make effect more direct, avoid that gastrointestinal bacterial flora between the individuality is active variantly to be caused the difference of metabolite and produce difference on the drug effect, thereby overcome the unmanageable problem of asiaticoside dosage, and improved bioavailability.
In addition, asiaticoside, the easy hydrolysis of asiaticoside, the preparation stability of its preparation is difficult to control, and its suitability for industrialized production is restricted; Asiatic acid of the present invention and derivatives chemical stable in properties thereof, antidepressant effect is obvious, so it is more suitable for the suitability for industrialized production of antidepressant drug.
Asiatic acid that reaches of the present invention and derivant thereof can also be applied to the patient who needs treatment with the form of compositions, and said compositions comprises asiatic acid and the derivant and the pharmaceutically acceptable carrier for the treatment of effective dose;
Said carrier comprises excipient, as starch, water etc.; Lubricant is as magnesium stearate etc.; Disintegrating agent is as microcrystalline Cellulose etc.; Filler is as lactose etc.; Bonding agent is as pregelatinized Starch, dextrin etc.;
Preferably contain percentage by weight and be 0.1～99.9% asiatic acid and derivant thereof;
The pharmaceutical composition of asiatic acid and derivant thereof can adopt method well known in the art to make various dosage forms, as tablet, capsule, granule, suspensoid, Emulsion, solution, syrup, injection etc., take oral or route of administration such as injection (comprising intravenous injection, intravenous drip, intramuscular injection, subcutaneous injection), mucosa dialysis are carried out the treatment of depression.
When being used for the patient, dosage is 0.6～60mg/kgd days, and this dosage determines according to the situation of patient's age and body weight and symptom usually.
Asiatic acid is the activity form of asiaticoside in the gastrointestinal tract biotransformation, directly uses asiatic acid, and the bioavailability of medicament height can accurately be controlled dosage.The asiatic acid stable in properties uses the quality of the pharmaceutical preparations of asiatic acid preparation stable.
Experimental results show that, asiatic acid of the present invention and derivant thereof, and pharmaceutical composition is the medicine of a kind of safe, efficient, stable, inexpensive prevention and treatment depression, all has higher activity, especially the activity of chemical compound such as asiatic acid, asiatic acid sodium is higher, is better than doxepin.
The specific embodiment
Specify content of the present invention below by embodiment.In the present invention, the example of the following stated is in order to set forth the present invention better, is not to be used for limiting the scope of the invention.
The preparation of embodiment 1, asiatic centella total aglycon tablet
Prescription:
Asiatic centella total aglycon 30g
Starch 30g
Lactose 40g
Carboxymethyl starch sodium 5g
Starch slurry (7%) is an amount of
Magnesium stearate 1% (1.25g)
Make 1000
Technology:
Get recipe quantity asiatic centella total aglycon, pulverized 100 mesh sieves, again starch, the lactose of recipe quantity were pulverized 100 mesh sieves, mixing.Asiatic acid, carboxymethyl starch sodium are added in the starch and lactose of mixing mixing.Add an amount of 7% starch slurry and mix thoroughly, granulate through 16 order ferrum silk screen nets, dry below 60 ℃, granulate adds an amount of magnesium stearate mixing, tabletting behind the analysis content.Can be made into 1000 every tablet tablet that contains 30mg asiatic centella total aglycon.
The preparation of embodiment 2, asiatic acid capsule
Prescription:
Asiatic acid 30g
Starch 160g
Starch silica gel 10g
Make 1000
Technology:
Get the acid of recipe quantity accumulated snow, pulverized 100 mesh sieves, in the starch of adding recipe quantity, the starch silica gel, mixing directly incapsulates, and can be made into 1000 every capsule that contains the 30mg asiatic acid.
The preparation of embodiment 3, asiatic acid sodium injection
Prescription:
Asiatic acid sodium 10g
Ethanol (95%) 4000g
Propylene glycol (C.P.) 1000g
Water for injection adds to 10000ml
Make 1000
Technology:
Get 20 ℃ of ethanol (95%) 5000g, add active carbon 5g and stir, through core group filtration under diminished pressure, standby.Getting recipe quantity asiatic acid sodium adds among the above-mentioned ethanol 4000g, be heated to about 50 ℃, fully stir, make it to dissolve clear and bright, add the recipe quantity propylene glycol then, add fresh water for injection again and make full dose become 10000ml, fully stir mixing, add active carbon 3g, clear and bright through core group filtration under diminished pressure, filtrate before and after merging is clear and bright with special-purpose core fine straining again.Check the qualified back embedding of content and clarity, 100 ℃ of circulation steam sterilization 30min promptly get the injection that every 10ml contains asiatic acid sodium 10mg.
The preparation of embodiment 4, asiatic centella total aglycon suspensoid
Prescription:
Asiatic centella total aglycon 300g
Sodium carboxymethyl cellulose (CMC) 100g
Distilled water adds to 100000ml
Make 1000 bottles
Technology:
Get recipe quantity asiatic centella total aglycon and be crushed to 200 orders, join among the CMC of the recipe quantity that swelling is good, stir, add distilled water, stir into suspendible, promptly get every milliliter of suspensoid that contains asiatic centella total aglycon 3mg to 100000ml.
The antidepressant effect experiment of embodiment 5, asiatic centella total aglycon
The main component of asiatic centella total aglycon comprises asiatic acid and Madecassic acid.The antidepressant effect of asiatic centella total aglycon adopts the desperate model of acquired mice (mouse tail suspension experiment and the experiment of mice forced swimming) to detect and verifies.
1. laboratory animal: 19～22 gram ICR male mices, per 10/cage group support is freely looked for food and is drunk water, room temperature (23 ± 2) ℃, natural lighting.
2. medicine preparation: with detected medicine (asiatic centella total aglycon, purchase in Guangxi Chang Zhou natural product development corporation, Ltd. lot number: 20021014, wherein asiatic acid accounts for 41%, Madecassic acid accounts for 54%) make suspensoid by embodiment 4 described methods, face the time spent to be made into desired concn.
3. experimental technique
A, mouse tail suspension experiment
The blank group: 10 of every treated animals give the CMC solution with medicine group isopyknic 0.1%;
The positive control drug group: 10 of every treated animals give the medicine doxepin, dosage 50mg/kg;
The trial drug group: 10 of every treated animals, give detected medicine (asiatic centella total aglycon), divide basic, normal, high dosage, be respectively 30mg/kg, 60mg/kg, 120mg/kg;
Every morning is irritated stomach once, successive administration 7 days.After the last administration 1 hour, 2 centimetres of positions of animal tail end are attached on the horizontal supports, make animal become the reversal of the natural order of things state, supporter is positioned in the open top container, about 5 centimetres away from bottom surface be on its head.Dead time in the record mice 6 minutes, each organizes the mice operation repetitive, the results are shown in Table 2.
Table 2, asiatic centella total aglycon are to mouse tail suspension experiment and the influence of forced swimming experiment dead time
( x±SD，n＝10)
| The outstanding tail experiment dead time (second) | The forced swimming experiment dead time (second) | |
| The heavy dose of group of dosage group (60mg/kg) (120mg/kg) in blank group doxepin group (50mg/kg) small dose group (30mg/kg) | 138.5±24.3 100.1±41.7 * 114.1±23.0 * 105.8±26.1 * 101.7±24.2 ** | 182.8±23.9 108.5±67.6 ** 150.6±46.4 147.2±43.8 * 140.5±36.4 ** |
*p＜0.05；
**p＜0.01
B, the experiment of mice forced swimming
Substantially carry out according to the Porsolt method.Medicine and dosage are tested with mouse tail suspension, and mice every morning is irritated stomach once, successive administration 7 days.After the last administration 1 hour, mice is put into the column type glass jar of 14 centimetres of high 20 centimetres, diameters separately, the depth of water is 10 centimetres in the cylinder, 23～25 ℃ of water temperatures.During from mice entry postscript 6 minutes, write down the accumulative total dead time in back 4 minutes, each organizes the mice operation repetitive.The results are shown in Table 2.
As can be seen from Table 2, basic, normal, high 3 dosage of asiatic centella total aglycon all can obviously shorten mouse tail suspension and forced swimming dead time, show that the asiatic centella total aglycon has tangible antidepressant effect.
The antidepressant effect experiment of embodiment 6, asiatic acid
The antidepressant effect of asiatic acid adopts the desperate model of acquired mice (mouse tail suspension experiment and the experiment of mice forced swimming) to detect and verifies.
1. laboratory animal: with embodiment 5.
2. medicine preparation: asiatic acid is purchased in Guangxi Chang Zhou natural product development corporation, Ltd., lot number: 20021014, and purity:
96.20%, method for preparation of drug is with embodiment 5.
3. experimental technique
A, mouse tail suspension experiment
Blank group: with embodiment 5;
Positive control drug group: with embodiment 5;
Trial drug group: with embodiment 5;
Operational approach the results are shown in Table 3 with embodiment 5.
Table 3, asiatic acid are to mouse tail suspension experiment and the influence of forced swimming experiment dead time
( x±SD，n＝10)
| The outstanding tail experiment dead time (second) | The forced swimming experiment dead time (second) | |
| The heavy dose of group of dosage group (60mg/kg) (120mg/kg) in blank group doxepin group (50mg/kg) small dose group (30mg/kg) | 138.5±24.3 100.1±41.7 * 104.4±25.7 * 87.9±30.1 ** 86.8±22.5 ** | 182.8±23.9 108.5±67.6 ** 159.9±24.3 * 156.5±28.5 * 147.5±29.3 ** |
*p＜0.05；
**p＜0.01
B, the experiment of mice forced swimming
With embodiment 5, the results are shown in Table 3.
As can be seen from Table 3, basic, normal, high 3 dosage of asiatic acid all can significantly shorten the mouse tail suspension dead time, obviously shorten the mice forced swimming dead time, show that asiatic acid has tangible antidepressant effect.
The antidepressant effect experiment of embodiment 7, Madecassic acid
The antidepressant effect of Madecassic acid adopts the desperate model of acquired mice (mouse tail suspension experiment and the experiment of mice forced swimming) to detect and verifies.
1. laboratory animal: with embodiment 5.
2. medicine preparation: Madecassic acid is purchased in Guangxi Chang Zhou natural product development corporation, Ltd., lot number: 20021014, and purity: 93.76%, method for preparation of drug is with embodiment 5.
3. experimental technique
A, mouse tail suspension experiment
Blank group: with embodiment 5;
Positive control drug group: with embodiment 5;
Trial drug group: with embodiment 5;
Operational approach the results are shown in Table 4 with embodiment 5.
B, the experiment of mice forced swimming
With embodiment 5, the results are shown in Table 4.
Table 4, Madecassic acid are to mouse tail suspension experiment and the influence of forced swimming experiment dead time
| The outstanding tail experiment dead time (second) | The forced swimming experiment dead time (second) | |
| The heavy dose of group of dosage group (60mg/kg) (120mg/kg) in blank group doxepin group (50mg/kg) small dose group (30mg/kg) | 138.5±24.3 100.1±41.7 * 110.5±30.6 * 107.4±37.4 * 97.7±25.4 ** | 182.8±23.9 108.5±67.6 ** 161.1±24.4 154.9±33.0 * 149.6±34.0 * |
*p＜0.05；
**p＜0.01
As can be seen from Table 4, basic, normal, high 3 dosage of Madecassic acid all can obviously shorten mouse tail suspension and forced swimming dead time, show that Madecassic acid has tangible antidepressant effect.
The antidepressant effect experiment of embodiment 8, asiatic acid sodium
The preparation of the salt derivative asiatic acid sodium of asiatic acid: under room temperature and stirring condition, with asiatic acid (4.89g, 95%7 alcoholic solutions (80ml) 10mmol) add respectively in 70% alcoholic solution (80ml) of sodium hydroxide (12mmol), add beginning after 15 minutes, the gained mixture was heated 20 minutes down at 50～60 ℃.Remove solvent under reduced pressure, washing residue 2 times is used 95% ethyl alcohol recrystallization, obtains asiatic acid sodium: white crystals, mp.312-314 ℃, 1H-NMR (500MHz, DMSO-d6) δ 5.14 (1H, brs, H-12), 2.11 (1H, d, H-18), 1.05,0.93,0.74,0.54 (each3H, s), 0.92,0.82 (each3H, d); With asiatic acid 1H-NMR collection of illustrative plates relatively δ 11.96 (1H, brs ,-COOH) the peak explanation asiatic acid that disappears has formed corresponding salt.
The antidepressant effect of asiatic acid sodium adopts the desperate model of acquired mice (mouse tail suspension experiment and the experiment of mice forced swimming) to detect and verifies.
1. laboratory animal: with embodiment 5.
2. medicine preparation: with embodiment 5.
3. experimental technique
A, mouse tail suspension experiment
Blank group: with embodiment 5;
Positive control drug group: with embodiment 5;
Trial drug group: with embodiment 5;
Operational approach the results are shown in Table 5 with embodiment 5.
B, the experiment of mice forced swimming
With embodiment 5, the results are shown in Table 5.
Table 5, asiatic acid sodium are to mouse tail suspension experiment and the influence of forced swimming experiment dead time
| The outstanding tail experiment dead time (second) | The forced swimming experiment dead time (second) | |
| The heavy dose of group of dosage group (60mg/kg) (120mg/kg) in blank group doxepin group (50mg/kg) small dose group (30mg/kg) | 138.5±24.3 100.1±41.7 * 106.7±24.6 * 89.5±28.0 ** 84.3±24.9 ** | 182.8±23.9 108.5±67.6 ** 155.3±26.2 * 151.4±27.1 * 148.8±30.7 ** |
*p＜0.05；
**p＜0.01
As can be seen from Table 5, basic, normal, high 3 dosage of asiatic acid sodium all can obviously shorten mouse tail suspension and forced swimming dead time, show that asiatic acid sodium has tangible antidepressant effect.
The reserpine antagonism experiment of embodiment 9, asiatic centella total aglycon, asiatic acid, Madecassic acid, asiatic acid sodium, asiatic acid methyl ester
1. laboratory animal: ICR male mice, 19～22 grams.
2. experimental technique: literature method is pressed in the influence to reserpine induced mice blepharoptosis.10 every group of mices are divided into 7 groups:
Blank group: give and the isopyknic 0.1%CMC solution of medicine group;
Positive control drug group: give the medicine doxepin, dosage 50mg/kg;
Herba Centellae total glycosides tuple: dosage 60mg/kg;
Asiatic acid group: the same;
Madecassic acid group: the same;
Asiatic acid sodium group: the same;
Asiatic acid methyl ester group: the same;
Behind the mouse tail vein injection reserpine 2mg/kg, intravenously administrable was immediately placed vertically 15 seconds animal is single after 60 minutes, observed the number of animals that blepharoptosis occurs, calculated antagonistic rate, the results are shown in Table 6.
Antagonistic rate (%)=(number of animals of every group of several blepharoptosiss of laboratory animal)/every group of laboratory animal number;
Table 6, asiatic centella total aglycon, asiatic acid, Madecassic acid, asiatic acid sodium, the antagonism of asiatic acid methyl ester reserpine
| Group | Dosage | Mice blepharoptosis number (only) | Antagonistic rate (%) |
| Blank group doxepin group asiaticoside tuple asiatic acid group brahmic acid group asiatic acid sodium asiatic acid methyl esters | 50mg/kg 60mg/kg 60mg/kg 60mg/kg 60mg/kg 60mg/kg | 0 6 3 3 4 2 3 | 0 40 70 70 60 80 70 |
As can be seen from Table 6, asiatic centella total aglycon, asiatic acid, Madecassic acid, asiatic acid sodium, asiatic acid methyl ester have antagonism to reserpine induced mice blepharoptosis, show that asiatic centella total aglycon, asiatic acid, Madecassic acid, asiatic acid sodium, asiatic acid methyl ester all have tangible antidepressant effect.
Claims (2)
1. the application of asiatic acid derivant in the preparation antidepressant drug that chemical structure of general formula is following
Wherein, R
1Be hydrogen or hydroxyl; R
2For hydrogen, contain straight or branched low alkyl group, alkali metal or the alkali earth metal of 1～4 carbon atom;
The straight or branched low alkyl group of said 1～4 carbon atom is a kind of in methyl, ethyl, propyl group, isopropyl, butyl, isobutyl group, the tert-butyl group or the sec-butyl.
2. application according to claim 1, it is characterized in that said asiatic acid derivant comprises a kind of of asiatic acid, asiatic acid methyl ester, asiatic acid ethyl ester, asiatic acid propyl ester, asiatic acid sodium, asiatic acid potassium, asiatic acid calcium, asiatic acid magnesium, Madecassic acid, Madecassic acid methyl ester, Madecassic acid ethyl ester, Madecassic acid propyl ester, Madecassic acid sodium, Madecassic acid potassium, Madecassic acid calcium, Madecassic acid magnesium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310108854 CN1256090C (en) | 2003-11-25 | 2003-11-25 | Application in antidepressants preparation of asiatic acid and derivation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310108854 CN1256090C (en) | 2003-11-25 | 2003-11-25 | Application in antidepressants preparation of asiatic acid and derivation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1543964A CN1543964A (en) | 2004-11-10 |
| CN1256090C true CN1256090C (en) | 2006-05-17 |
Family
ID=34334897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310108854 Expired - Fee Related CN1256090C (en) | 2003-11-25 | 2003-11-25 | Application in antidepressants preparation of asiatic acid and derivation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1256090C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011047576A1 (en) | 2009-10-20 | 2011-04-28 | Zhang Zuoguang | Use of albiflorin for anti-depression |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101969942A (en) * | 2008-01-11 | 2011-02-09 | 上海医药工业研究院 | Therapeutic formulations based on asiatic acid and selected salts thereof |
| CN102641273A (en) * | 2011-02-17 | 2012-08-22 | 苏州迪星生物医药科技有限公司 | New application of asiatic acid and derivatives thereof |
| CN102690314B (en) * | 2011-03-22 | 2015-06-10 | 上海医药工业研究院 | Amorphous asiatic acid tromethamine salt and its preparation method |
| CN102755328B (en) * | 2011-04-29 | 2015-05-06 | 上海医药工业研究院 | Asiatate microemulsion soft capsule and preparation method thereof |
| CN103816164B (en) * | 2014-01-26 | 2015-07-08 | 中国人民解放军第二军医大学 | Application of asiatic acid derivative A1 in preparation of anti-depression drug |
| CN104829677B (en) * | 2014-02-10 | 2017-06-06 | 上海医药工业研究院 | A kind of brahmic acid salt and its production and use |
| CN104829678B (en) * | 2014-02-10 | 2017-01-11 | 上海医药工业研究院 | Asiatic acid salt, preparation method and application thereof |
| CN103980339B (en) * | 2014-05-14 | 2016-04-27 | 中国人民解放军第二军医大学 | Accumulated snow oxalyl-L-Trp and preparing the application in antidepressant drug |
| CN104961790B (en) * | 2015-05-18 | 2019-03-26 | 中国人民解放军海军医学研究所 | Asiatic acid derivative, preparation method and its application in preparation antidepressant |
-
2003
- 2003-11-25 CN CN 200310108854 patent/CN1256090C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011047576A1 (en) | 2009-10-20 | 2011-04-28 | Zhang Zuoguang | Use of albiflorin for anti-depression |
| US9023817B2 (en) | 2009-10-20 | 2015-05-05 | Zuoguang Zhang | Use of albiflorin for anti-depression |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1543964A (en) | 2004-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1279903C (en) | Preparation containing Gingkolactone and its producing process | |
| CN1256090C (en) | Application in antidepressants preparation of asiatic acid and derivation | |
| CN1733766A (en) | Cough and phlegm removing purple bergenia element analog and its pharmaceutical composition | |
| CN1686458A (en) | Chinese medicinal composition, its preparation method and use | |
| CN1161389C (en) | Preparing process and use of ginkgo leaf polypentenol and ginkgo leaf extract | |
| CN1813900A (en) | Kadsura longipedunculata lignin extract and its preparing method and use | |
| CN1245972C (en) | Naringin and its salt used for preparing cough suppressing phlegm tramsforming medicine | |
| CN1803787A (en) | Hypericum perforatum L. total flavone extracts, its preparation and application | |
| CN1733054A (en) | Dogwood fruit extract and its preparation process | |
| CN1813860A (en) | Dispersible tablet for clearing away heat of brain and heart and preparation process thereof | |
| CN1186051C (en) | 'Huajuhong' preparation and its preparing process | |
| CN1511520A (en) | Use of succinate derivative for biologically treating dementia | |
| CN1316960C (en) | Compound mactra clam drip pill and its preparation method | |
| CN1720948A (en) | Dripping pills of lllicium henryi dripping pills and method for preparing the same | |
| CN1821255A (en) | Total giamt St.John' swort Herb flavone extract, its preparing method and use | |
| CN1616060A (en) | Chinese medicine drippling pill preparation for promoting blood circulation and removing blood stasis, promoting Qi circulation and rilieving pain | |
| CN1723030A (en) | Remedies or preventing for allergic diseases comprising processed peanut seed coat | |
| CN1557824A (en) | Silkworm excrement total alkaloid and its preparation method | |
| CN1297254C (en) | Drop pills containing bear gall and tendril-leaved fritillary bulb and preparation method thereof | |
| CN1682821A (en) | Compound radical lobelia dripping pill and its preparing method | |
| CN1742783A (en) | Natural medicine preparatino for tonifying Qi strengthening body resistance and preparing method | |
| CN1394603A (en) | Application of hydroxyethyl puerarin in preparation of new medicine for curing cerebrovascular diseases | |
| CN1634481A (en) | Honeysuckle flower soft capsule and preparation method thereof | |
| CN1309379C (en) | Asari dripping pills and its preparation process | |
| CN1895495A (en) | Hericiaceae contained Jianweiling capsules for stomach disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060517 Termination date: 20121125 |